Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform

Masking Technology Could Address Safety Limitations Of Solid Tumor Candidates

Executive Summary

The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.

You may also be interested in...



Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'

The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel